4 active not recruiting, 4 recruiting, 3 completed. 9 Phase 2, 1 Phase 1, 1 Phase 3.
By phase and status
Follow lutikizumab: new trials by email Literature Review of lutikizumab trials Research Report on lutikizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Lutikizumab, Placebo, Ravagalimab - Rheumatoid Arthritis Phase 2 Recruiting 180 2025-06-20 2026-10-08 Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis Lutikizumab, Risankizumab - Psoriatic Arthritis Phase 2 Recruiting 120 2025-04-11 2025-12-18 A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis Lutikizumab, Placebo - Atopic Dermatitis Phase 2 Active not recruiting 83 2024-12-19 2026-08-14 Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease Risankizumab, Lutikizumab, Trosunilimab - Crohn's Disease Phase 2 Recruiting 590 2024-09-04 2026-09-25 A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab Lutikizumab - Hidradenitis Suppurativa, Atopic Dermatitis Phase 2 Recruiting 60 2024-08-14 2025-01-24 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Lutikizumab, Placebo - Hidradenitis Suppurativa Phase 3 Active not recruiting 1400 2024-06-27 2026-09-02 A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis Lutikizumab, Adalimumab - Ulcerative Colitis Phase 2 Active not recruiting 156 2024-03-23 2025-10-07 A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy Lutikizumab, Placebo - Hidradenitis Suppurativa Phase 2 Active not recruiting 210 2021-12-28 2026-02-13 A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis ABT-981, Placebo for ABT-981 - Erosive Hand Osteoarthritis Phase 2 Completed 132 2015-03-01 2017-08-11 A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis ABT-981, Placebo - Knee Osteoarthritis, Medial Compartment Knee Osteoarthritis Phase 2 Completed 350 2014-06-04 2019-08-28 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee ABT-981, Placebo - Osteoarthritis Phase 1 Completed 36 2012-09-01 2017-11-20
Conditions studied Hidradenitis Suppurativa (3) · Osteoarthritis (3) · Dermatitis, Atopic (2) · Arthritis (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Joint Diseases (1) · Musculoskeletal Diseases (1) · Osteoarthritis, Knee (1) · Pain (1) · Rheumatic Diseases (1) · Synovitis (1)
Sponsors AbbVie (10) · AbbVie (prior sponsor, Abbott) (1)
Countries United States (9) · Canada (6) · Germany (5) · Hungary (5) · Poland (5) · South Korea (5) · Spain (5) · Czechia (4) · France (4) · Japan (4) · Puerto Rico (4) · Serbia (4) · Taiwan (4) · United Kingdom (4) · Australia (3)
Top investigators Marc Levesque, MD (1) · Susanne X. Wang, MD (1)
Results publications PMID 28964890 , PMID 30552176 , PMID 30653843 , PMID 41848710
NIH funding 2014 (1) , 2023 (1) , 2025 (1)